NVAX on a 120 minute chart demonstrates a trend down in the past month after a period of consolidation producing the POC line on the volume profile. The MACD shows some bullish divergence. The volume profile has high volume nodes at 4.0 and 5.0 separated by a relative volume void. NVAX fell quickly through that void. It can just as easily rise through it....
NVAX on the 15 minute chart has been compressing price action volatility into a symmetrical triangle. It in now in a breakout of the triangle and in the process when from undervalued on Monday to the upper trendline and then down to the support trendline and then up again. It passed through the volume profile and its high volume area. In short, it has bullish...
The mRNA stock has exhibited a bullish flag breakout, following the identification of a falling wedge pattern. We anticipate a potential retracement towards the prominent key level near $130, which was established at the top.
Moderna ( NASDAQ:MRNA ), the pioneering vaccine maker, reported a surprise fourth-quarter profit, sending ripples of optimism through the market. Bolstered by unexpected revenue and strategic cost-cutting measures, the company's resilience amid shifting tides in the pharmaceutical landscape has drawn both attention and applause. Unveiling the Numbers: Moderna's (...
Moderna has recently garnered attention for its significant rebound after a challenging 2023. The biotech company, primarily known for its groundbreaking COVID-19 vaccine, is poised for a transformative journey ahead, with a strategic pipeline that extends far beyond pandemic management. This Idea delves into the recent surge in Moderna's stock, the pivotal role...
Moderna has had an astronomical rise due to the vaccine. The technical setup looks excellent to the short side. TD9's on the daily, 2 day, 3 day, big divergences on many timeframes. That said - there is headline risk with this - if they get FDA approval it would likely squeeze.
Moderna Inc.’s stock soared 14% early Thursday to early Friday after the biotech company and partner Merck & Co. announced positive data from a trial of Moderna’s mRNA-4157 in combination with Merck’s blockbuster cancer drug Keytruda in patients with resected high-risk melanoma (stage III/IV). The companies said that after about three years, the combination...
Its way overbought and numbers looks good. Technically sitting at a good support and can jump anytime. Within 3-5 years, it can give you back 70% gains.
We are in a major daily demand zone here, I will be looking for prices to bounce off of these levels with substantial volume and will hold some long calls. Thank you for partaking of my analysis.
Its right at the support line and could rally towards 160. It must stay above 95, otherwise its going further down. Its tech analysis and not any advice to buy/sell.
This is a Technical Analysis on Moderna (MRNA) on the 1 Week Timeframe. Current price action shows that we are currently in the process of breaking a MAJOR SUPPORT Zone. We held critical SUPPORT multiple times ABOVE the $115.00 level, for a span of about 26 months. Expressed by the GREEN circles. But notice we havent been able to successfully rally and stay...
Hello everyone Josh here again. I’m sure by now you’ve already heard mumblings of Covid’s imminent return. We are seeing everything from colleges to hospitals start to implement Covid policies. The news cycle is starting to warn of a dangerous flu season/Covid return. Governments around the world are now updating their Covid policies and sleepy Joe’s White House...
NVAX could be forming a large Weekly Inverse Head & Shoulder. If this pattern is to break out, it likely means we have new Covid strains and potential lockdowns.
BNTX a Germany company in the biotechnology and vaccine sectors out of Europe and Germany is looking good on the 2H chart here with a volume profile and an intermediate term VWAP overlaid. Price bounced off the bottom of the high volume area of the volume profile and looks to be ready for a reversion to the mean and even a sling-short move. The target here is...
MRNA is a medical technology company. It is in the vaccine sector and competes ( well) with NVAX and PFE among others. Earnings are upcoming on 8/3 in about a week. On the 30 minute chart it appears to be in a descending wedge pattern which is typically a bottoming with a breakout over and beyond the descending trendline. The relative trend indicator shows...
Discussing a potential capital rotation trade. We analyze Tesla, Amazon, Pfizer, Moderna, Hershey, and others to get a sense of what is going on.
Hello Folks, We can see Falling Wedge pattern clearly at MRNA with RSI positive divergence. I consider it important that this image is formed at a significant level of horizontal support. As a condition to enter the position, it would be reasonable to wait for the formation of a new high.
NVAX has had significant down trending over a wide range of time. On the 4H chart it seems to be pivoting from a swing bottom 3-4 days ago. This is accompanied by a cross of the MACD lines under the histogram on that indicator and a flip of volatility on the relative volatility indicator. NVAX has been subject to significant short selling. Price is presently...